Genmab and Seagen reach primary endpoints in Phase III cervical cancer study

The results expand on previous results from earlier trials.

Genmab har sammen med partneren Seagen med lægemidlet Tikdav nået de primære endemål i et fase 3-studie af andenlinje-behandling af patienter med tilbagevendende eller metastatisk livmoderhalskræft. | Photo: Medwatch

af marketwire

Genmab and Seagen have met primary endpoints in a Phase III study of second-line treatment with the drug Tivdak (tisotumab vedotin-tftv) in patients with recurrent or metastatic cervical cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Photo: Mike Segar/Reuters/Ritzau Scanpix

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Photo: Alexander Heinl/AP/Ritzau Scanpix

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Photo: Genmab / PR

Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers

Pharma & biotech

Genmab and Abbvie receives EU clearance to market cancer drug

The drug has previously received a positive recommendation from European Medicines Agency, while it was launched in the US by the end of the second quarter.

For subscribers